A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients

作者：Perez Pitarch Alejandro^*; Ferriols Lisart Rafael; Alos Alminana Manuel; Minguez Perez Miguel

来源：Revista Espanola de Enfermedades Digestivas, 2015, 107(3): 137-142.

• Infliximab
• Pharmacokinetics
• Colitis
• Ulcerative

Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab.
Aims: To explore optimal dosing strategies of infliximab in treatment-naive patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model.
Methods: A population of 2,000 treatment-nave patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this population. Strategies 1 and 2 consisted on 5 mg/kg and 6 mg/kg doses, respectively, and 8 weeks inter-dose interval. Strategies 3 and 4 used Individualized doses, adjusted to albumin level, sex and body weight, and a fix inter-dose interval of 8 weeks to achieve a target trough concentration of 5 mg/L or 6 mg/L, respectively. Strategies 5 and 6 used a fix dose of 5 mg/kg and individualized inter-dose intervals, adjusted to the same covariates, to achieve a target concentration, of 5 mg/L or 6 mg/L, respectively.
Results: Strategies 2-6 reached trough levels statistically higher than strategy 1 (p < 0.05). Strategy 5 proved to be the best dosing strategy. It was associated with a higher proportion of responder patients than strategy 1 (62 % vs. 40 %) without reaching higher peak concentrations.
Conclusions: Optimization of maintenance treatment of colitis with infliximab by a pharmacokinetic approach could benefit infliximab-naive patients with ulcerative colitis.

• 出版日期2015-3